Search - tctmd.com

Displaying 901 - 920 of 1134

Sort: Relevancy | Date

Presentation TCT 2017

Futuristic and Novel #1: The Promise of Tissue Engineered Bioprosthetic Heart Valves (Both Surgical and Transcatheter) is Within Reach

Presenter: Robert O. Bonow, Michael J. Mack, Maximilian Y Emmert

October 30, 2017

Presentation TCT 2017

From Traditional Society Guidelines to Rapid Communications (e.g. BMJ WikiRecs): Evidence Development, Clinical Practice Standards, and Treatment Recommendations

Presenter: Robert O. Bonow, Michael J. Mack, David Hildick-Smith

October 30, 2017

Presentation TCT 2017

Aortic Stenosis Population Oddities Who are the Patients Not Being Diagnosed or Treated?

Presenter: Robert O. Bonow, Michael J. Mack, Maurice E. Sarano

October 30, 2017

Presentation TCT 2017

Counterpoint Access to Modern Valve Therapies for Underserved Populations Trumps Arbitrary Guidelines Favoring High-Volume Urban Centers!

Presenter: Uzoma Ibebuogu

October 30, 2017

Presentation TCT 2017

Point A Tiered Centers of Excellence Approach Makes Sense!

Presenter: Patrick T. O'Gara

October 30, 2017

Presentation TCT 2017

Counterpoint In the Modern Era, Crowd Wisdom, Cumulative Experience and New Technology Trumps Case Volume!

Presenter: Martin B. Leon

October 30, 2017

Presentation TCT 2017

Point - Clearly, The More You Do, The Better You Are!

Presenter: John D. Carroll

October 30, 2017

Presentation TCT 2017

Featured Lecture: The Vancouver Multidisciplinary, Multimodality, but Minimalist Clinical Pathway Facilitates Safe Next Day Discharge Home at Low, Medium, and High Volume Transcatheter Aortic Valve Replacement Centres: the 3M TAVR Study

Presenter: Robert O. Bonow, Michael J. Mack, David A. Wood

October 30, 2017

Presentation TCT 2017

Staging Classification of Aortic Stenosis Based Upon the Extent of Cardiac Damage A Novel Concept

Presenter: Robert O. Bonow, Michael J. Mack, Philippe Genereux

October 30, 2017

Presentation TCT 2017

Refining the Classic Definition of Aortic Stenosis: A Dynamic Interpretation Including the Role of Ventricular Stroke Work and Vascular Impedance

Presenter: Robert O. Bonow, Michael J. Mack, Elazer R. Edelman

October 30, 2017

Presentation TCT 2017

Germany Comments: How Would I Treat This Case and Why?

Presenter: Petr Kala, Jochen Wöhrle, Thomas Walther

October 30, 2017

Presentation TCT 2017

Czech Republic Comments: How Would I Treat This Case and Why?

Presenter: Petr Kala, Jochen Wöhrle, Marian Branny

October 30, 2017

Presentation TCT 2017

Slovakia Presents: Current Knowledge Impact of Coronary Artery Disease on TAVR Management and Outcomes

Presenter: Petr Kala, Jochen Wöhrle, Martin Hudec

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey V: Addressing Complications and Follow-up

Presenter: Martina Kelly Speight, Amy E. Simone

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey IV: The Hospital Experience

Presenter: Martina Kelly Speight, Sandra Lauck

October 30, 2017

Presentation TCT 2017

TAVR should be reserved for intermediate and higher-risk tricuspid valve aortic stenosis!

Presenter: A. Pieter Kappetein

October 30, 2017

Presentation TCT 2017

Were ready to treat bicuspid valve and lower-risk tricuspid valve aortic stenosis!

Presenter: Susheel K. Kodali

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey III: Behind the Scenes

Presenter: Martina Kelly Speight, Sarah Clarke

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey II: Imaging Assessment

Presenter: Martina Kelly Speight, João L Cavalcante

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey I: Initial Evaluation

Presenter: Martina Kelly Speight, Patricia Keegan

October 30, 2017

Advertisement

Futuristic and Novel #1: The Promise of Tissue Engineered Bioprosthetic Heart Valves (Both Surgical and Transcatheter) is Within Reach

From Traditional Society Guidelines to Rapid Communications (e.g. BMJ WikiRecs): Evidence Development, Clinical Practice Standards, and Treatment Recommendations

Aortic Stenosis Population Oddities Who are the Patients Not Being Diagnosed or Treated?

Counterpoint Access to Modern Valve Therapies for Underserved Populations Trumps Arbitrary Guidelines Favoring High-Volume Urban Centers!

Point A Tiered Centers of Excellence Approach Makes Sense!

Counterpoint In the Modern Era, Crowd Wisdom, Cumulative Experience and New Technology Trumps Case Volume!

Point - Clearly, The More You Do, The Better You Are!

Featured Lecture: The Vancouver Multidisciplinary, Multimodality, but Minimalist Clinical Pathway Facilitates Safe Next Day Discharge Home at Low, Medium, and High Volume Transcatheter Aortic Valve Replacement Centres: the 3M TAVR Study

Staging Classification of Aortic Stenosis Based Upon the Extent of Cardiac Damage A Novel Concept

Refining the Classic Definition of Aortic Stenosis: A Dynamic Interpretation Including the Role of Ventricular Stroke Work and Vascular Impedance

Germany Comments: How Would I Treat This Case and Why?

Czech Republic Comments: How Would I Treat This Case and Why?

Slovakia Presents: Current Knowledge Impact of Coronary Artery Disease on TAVR Management and Outcomes

TAVR Patient Journey V: Addressing Complications and Follow-up

TAVR Patient Journey IV: The Hospital Experience

TAVR should be reserved for intermediate and higher-risk tricuspid valve aortic stenosis!

Were ready to treat bicuspid valve and lower-risk tricuspid valve aortic stenosis!

TAVR Patient Journey III: Behind the Scenes

TAVR Patient Journey II: Imaging Assessment

TAVR Patient Journey I: Initial Evaluation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content